Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
In the coronavirus (CoV) disease 2019 (COVID-19) pandemic, highly selective serological testing is essential to define exposure to severe acute respiratory syndrome CoV 2 (SARS-CoV-2). Many tests have been developed, yet with variable speeds to first results, and are of unknown quality, particularly when considering the prediction of neutralizing capacity. The LIAISON SARS-CoV-2 S1/S2 IgG assay was designed to measure antibodies against the SARS-CoV-2 native S1/S2 proteins in a standardized automated chemiluminescence assay.
Article activity feed
-
-
SciScore for 10.1101/2020.05.19.105445: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The protocol for this study (de-identified remainders) was determined to be exempt under existing ethics committee regulations. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources SARS-CoV-2 S1/S2 IgG chemiluminescent assay is a recently developed assay from DiaSorin designed to detect IgG antibodies in the serum or plasma of subjects and patients exposed to the SARS-CoV-2 virus. detect IgGsuggested: NoneExperimental Models: Cell Lines Sentences Resources Recombinant fusion antigens were expressed in human cells … SciScore for 10.1101/2020.05.19.105445: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The protocol for this study (de-identified remainders) was determined to be exempt under existing ethics committee regulations. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources SARS-CoV-2 S1/S2 IgG chemiluminescent assay is a recently developed assay from DiaSorin designed to detect IgG antibodies in the serum or plasma of subjects and patients exposed to the SARS-CoV-2 virus. detect IgGsuggested: NoneExperimental Models: Cell Lines Sentences Resources Recombinant fusion antigens were expressed in human cells (HEK-293) to ensure proper folding, oligomer formation and glycosylation, providing capture moieties more similar to the viral Spike proteins, as processed by natural cellular cleavage (20-22): this distinguishes the DiaSorin CLIA from commonly used ELISAs where the antigens are presented on plastic plate surfaces, and are susceptible to significant denaturation consequent to passive adsorption to these hydrophobic surfaces (23, 24). HEK-293suggested: NoneBriefly, 50 μl of diluted serum (4-fold serial dilutions from 1:10 to 1:640) were added to an equal volume of viral suspension (tissue culture infectious dose 50 of a SARS-CoV2 strain isolated from a symptomatic patient), incubated, and then combined with Vero-E6 cells. Vero-E6suggested: NoneSoftware and Algorithms Sentences Resources Statistical analyses: The statistical program R 3.5 and MedCalc 19.2 were utilized for all analyses presented. MedCalcsuggested: (MedCalc, RRID:SCR_015044)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-